From bloodjournal.hematologylibrary.org by guest on June 4, 2013. For personal use only.
Prepublished online October 4, 2007; doi:10.1182/blood-2007-07-098483
Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia Mohamed L Sorror, Barry E Storer, David G. Maloney, Brenda M. Sandmaier, Paul J. Martin and Rainer Storb
Articles on similar topics can be found in the following Blood collections Clinical Trials and Observations (3716 articles) Free Research Articles (1730 articles) Neoplasia (4217 articles) Transplantation (1880 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml
Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.
From bloodjournal.hematologylibrary.org by guest on June 4, 2013. For personal use only.
Blood First Edition Paper, prepublished online October 4, 2007; DOI 10.1182/blood-2007-07-098483
Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia
Mohamed L. Sorror1, Barry E. Storer1,2, David G. Maloney1,2, Brenda M. Sandmaier1,2, Paul J. Martin1,2, and Rainer Storb1,2 Fred Hutchinson Cancer Research Center and the 2Department of Medicine at University of
1
Washington School of Medicine, Seattle, WA.
Supported in part by grants CA78902, CA18029, CA15704, and HL088021 from the National Institutes of Health, Bethesda, MD and in part by the Paros Family Fund. Correspondence and reprints to: Mohamed Sorror, M.D., Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., D1-100, P.O. Box 19024, Seattle, WA 98109-1024, Telephone: (206) 667-2765, FAX: (206) 667-6124, e-mail:
[email protected] Short title: Allogeneic transplant, lymphoma, CLL, comorbidity
Key Words: Hematopoietic cell transplantation; non-Hodgkin lymphoma; Hodgkin lymphoma; and chronic lymphocytic leukemia; nonmyeloablative conditioning; myeloablative conditioning; and hematopoietic cell transplantation-specific comorbidity index.
1
Copyright © 2007 American Society of Hematology
From bloodjournal.hematologylibrary.org by guest on June 4, 2013. For personal use only.
ABSTRACT
Allogeneic conventional hematopoietic cell transplantation (HCT) can be curative treatment for lymphoid malignancies, but it has been characterized by high non-relapse mortality (NRM). Here, we compared outcomes among patients with lymphoma or chronic lymphocytic leukemia given either nonmyeloablative (n=152) or myeloablative (n=68) conditioning. Outcomes were stratified by the HCT-specific comorbidity index. Patients in the nonmyeloablative group were older, had more prior treatment and more comorbidities, more frequently had unrelated donors, and more often had malignancy in remission compared to patients in the myeloablative group. Patients with indolent versus aggressive malignancies were equally distributed among both cohorts. After HCT, patients without comorbidities both in the nonmyeloablative and myeloablative cohorts had comparable NRM (p=0.74), overall survival (p=0.75) and progression-free survival (p=0.40). No significant differences were observed (p=0.91, p=0.89, and p=0.40, respectively) after adjustment for pretransplant variables. Patients with comorbidities experienced lower NRM (p=0.009) and better survival (p=0.04) after nonmyeloablative conditioning. These differences became more significant (p
